BNZ-1

BNZ-1 is a first-in-class, pegylated 19-mer peptide that acts as a selective and simultaneous inhibitor of the cytokines interleukin-2 (IL-2), interleukin-9 (IL-9), and interleukin-15 (IL-15) by blocking their binding to the common gamma chain (\(\gamma_c\)) receptor subunit. This mechanism disrupts signaling pathways implicated in multiple T-cell malignancies and autoimmune diseases. BNZ-1 has demonstrated clinical proof-of-concept in cutaneous T-cell lymphoma (CTCL) with favorable safety, tolerability, and clinically meaningful improvements in disease scores. It is also being developed for alopecia areata. The drug was originally developed by Bioniz Therapeutics and later acquired by Equillium[1][2][3][4][5][7].

Brand names

EQ101EQ-101EQ 101

Other names

BNZ-1BNZ1BNZ 1BNZ132-1BNZ-132-1BNZ 132-1BNZ132-1-40BNZ-132-1-40BNZ 132-1-40EQ-101EQ101EQ 101